Skip to main content
  • ‘Crowd and Mask’ Monitoring System to prevent COVID-19

    Innovators at Indian Institute of Science Education and Research (IISER), Bhopal have developed a unique ‘Crowd and Mask’ Monitoring System to prevent COVID-19 from spread. This one-of-its-kind low cost Artificial Intelligence (AI)-enabled device is portable and easy to deploy across various locations, says a statement released by the institution.

  • Novel technique may help in early detection of Cancer, Alzheimer’s, and Parkinson’s

    Scientists from Raman Research Institute (RRI) have developed a new technique to measure DNA modifications that can have applications in the early diagnosis of multiple diseases like Cancer, Alzheimer’s, and Parkinson’s diseases.

  • Medtronic Launches TYRX™ Envelope in India

    India Medtronic Private Limited, a wholly owned subsidiary of Medtronic plc announced the launch of the TYRX™ Absorbable Antibacterial Envelope (TYRX Envelope) - an absorbable, single-use, antibacterial envelope designed to stabilize a cardiac implantable electronic device (CIED) or implanted neurostimulator while releasing antimicrobial agents over a minimum of seven days.

    admin Thu, 02/25/2021 - 15:13
  • Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax’ and Moderna’s COVID-19 Vaccine Candidates in Japan

    Takeda Pharmaceutical Company Limited announced that the first subject was dosed in its Phase 1/2 immunogenicity and safety study of Novavax’ COVID-19 vaccine candidate (TAK-019) in Japan. Earlier this month, Takeda completed enrollment in the company’s Phase 1/2 immunogenicity and safety study of Moderna’s COVID-19 vaccine candidate (TAK-919) in Japan.

    admin Thu, 02/25/2021 - 15:06
  • Moderna sends COVID-19 booster shot for NIH testing

    Moderna, Inc a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announces that it has completed manufacturing of clinical trial material for its variant-specific vaccine candidate, mRNA-1273.351, against the SARS-CoV-2 variant known as B.1.351 first identified in the Republic of South Africa, and has shipped doses to the National Institutes of Health (NIH) for a Phase 1 clinical trial that will be led and funded by the NIH’s National Institute of Allergy and Infectious Diseases (NIAID).

    admin Thu, 02/25/2021 - 14:55
  • Government includes non-alcoholic fatty liver into National Program

    Union Health Minister Dr. Harsh Vardhan on Monday announced inclusion of “non-alcoholic fatty liver disease” into the National Programme for Prevention & Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS), a move that will help manage the country’s burden of non-communicable diseases.

    admin Wed, 02/24/2021 - 16:57
  • Neurologists Identify Consistent Neuroinflammatory Response in ICH Patients

    Understanding how the immune system responds to acute brain hemorrhage could open doors to identifying treatments for this devastating disease. However, up until now, there has been limited information on inflammation in the brain from human patients, especially during the first days after a hemorrhagic stroke.

    This led a team of researchers to partner with a large clinical trial of minimally-invasive surgery to tackle defining the human neuroinflammatory response in living patients.

    admin Tue, 02/23/2021 - 16:27
  • New potential drug to treat SARS-CoV-2

    A federally approved heart medication shows significant effectiveness in interfering with SARS-CoV-2 entry into the human cell host, according to a new study by a research team from Texas A&M University and The University of Texas Medical Branch (UTMB).

    The medication bepridil, which goes by the trade name Vascor, is currently approved by the U.S. Food and Drug Administration (FDA) to treat angina, a heart condition.

    admin Tue, 02/23/2021 - 16:21
  • Astrazeneca withdraws Imfinzi indication in advanced bladder cancer in FDA

    AstraZeneca announced the voluntary withdrawal of the Imfinzi (durvalumab) indication in the US for previously treated adult patients with locally advanced or metastatic bladder cancer. This decision was made in consultation with the Food and Drug Administration (FDA).

    admin Tue, 02/23/2021 - 16:15
  • Laipac Technology to Launch World’s First AI Rapid Antigen Test System

    The LooK SPOT solution is an intelligent and innovative way to deploy technologies to better protect the health of people across the region. Being able to have a quick and accurate COVID-19 diagnosis can interrupt transmission, aid clinical management, and help proper allocation of resources to isolation.

    admin Tue, 02/23/2021 - 16:10
Subscribe to Pharma News